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Background
Hailed as the gold standard in clinical evaluation, the 
randomized controlled trial (RCT) has become a central 
feature of the development of new drugs and medical 
devices. As May has noted, the symbolic capital of the 
clinical trial arises in part from the purity of the design 
and associated scientiﬁ   c rigour; the RCT is the 
touchstone of clinical epidemiology, and the standard 
against which other research and reputations are 
measured [1]. Indeed, underscoring its privileged place 
within the medical sciences, it has been said in relation to 
the RCT that “our ability to evaluate rigorously what we 
do clinically remains the essence of modern biomedicine” 
[2]. Th  is is nowhere more true than in the ﬁ  eld of HIV 
treatment and prevention [3].
Th  e RCT is posited as the ideal experiment. Placebo 
control, blinding and randomization – enshrined in 
rigorous trial protocols that get imposed on everyday life 
and clinical practice – are designed to minimize social 
contingencies and allow the objective, a-contextual 
measurement of reality. Methods are based on a positivist 
paradigm that assumes the existence of a single, ﬁ  xed 
reality and the possibility of neutral, objective and value-
free knowledge of that reality. It is these measurement 
ideals, embodied in RCT methodology, that assure the 
RCT its hallowed place in medical research, at the very 
heart of evidence-based medicine (EBM).
However, it is these very same ideals and methodo-
logical assumptions that lead some social scientists to 
critique the RCT (and EBM more broadly), arguing that 
it relies on human decisions about classiﬁ  cation that are 
deeply embedded in cultural conventions. Th  us it has 
been argued that the RCT does not simply describe 
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view is based on constructivist and interpretivist para-
digms that assume multiple, context-dependent and 
historically contingent realities, inﬂ  uenced or produced 
by the values of the researcher and by the research 
process itself (for an overview of EBM in relation to 
social science critiques, see [6]).
Such fundamental diﬀ   erences in ontology and epi-
stemo  logy have been seen to map unproblematically onto 
the medical and the social sciences. Th  e presumed 
antipathy between the two has spawned numerous 
critical assessments of collaboration in both directions 
(epitomized by the so-called “paradigm wars” [7]), with 
the social sciences calling into question the credibility 
and objectivity of RCT evidence, and medical researchers 
deeply suspicious of what counts as evidence in the social 
sciences. For example, Pareja Béhague et al report that 
anthropological work is often regarded as soft, anecdotal 
and biased by virtue of the fact that it is based on small 
numbers of purposively selected informants. It is there-
fore deemed subjective rather than scientiﬁ  c [8]. Further-
more, while social scientists working with medical 
researchers may be expected to be conversant with 
epidemiological concepts and terminology, reference to 
social theorists among clinical epidemiologists is likely to 
be met with blank faces. Against this backdrop, 
Napolitano and Jones propose that “those belonging to 
the culture of social science and those belonging to the 
culture of medicine still appear to exist in almost totally 
separate conceptual universes” [9].
But how monolithic is the distinction between social 
and biomedical researchers? While the RCT itself embodies 
a regulated and standardized structure of evidence 
making, collaborators on a trial may espouse a variety of 
philosophical and methodological positions. Diversity 
may exist not only between biomedical and social 
researchers, but also between social scientists and among 
qualitative researchers [10, 11]. For example, a wide range 
of theoretical and methodological views are represented 
by people deﬁ  ning themselves as social scientists. Many 
social scientists, including some ethnographers, use 
positivist methods and approaches. Some social scientists 
using quantitative methods adopt a critical, non-
positivist approach to their methods and data; see for 
example [12]. Th  is suggests the potential for successful 
collaboration between disciplinary teams working on 
HIV trials. It also suggests, however, that bridging the 
social and the biomedical does not concern a simple 
dichotomy but a more nuanced set of tensions that 
traverse epistemological, methodological and disciplinary 
dispositions.
Th  e negotiation of these tensions grows ever more 
pertinent; in recent years, it has not only become 
increasingly acceptable to include social science in HIV 
trials, but there is great demand for mixed-method 
research from biomedical researchers and funders alike. 
Th  ere are various reasons for this. HIV interventionists 
want to be able to change beliefs, attitudes and 
behaviours contributing to new infections, and medical 
researchers need to ensure that people are motivated to 
enrol in trials, adhere to regimens and procedures, and 
are retained. Data on adherence and acceptability are 
essential: it is pointless developing and testing an 
intervention or new drug if people end up not wanting to 
use it. Th  ese are all inherently sociological issues that 
require a more qualitative approach, and an awareness of 
this has developed in medical research settings over the 
past 20 years.
In this paper, we describe collaboration between social 
and biomedical researchers on a large, publicly funded 
programme to develop vaginal microbicides for HIV 
prevention. Although the term “social science” can en-
compass many diﬀ  erent disciplines, from economics to 
psychology, we use it here in a more limited sense to refer 
to the study of the social world using anthropological and 
sociological methods and perspectives. Our own 
intellectual position is located broadly within social 
constructivism and critical anthropology, and it is these 
traditions that inform the discussion that follows. 
Constructivism refers to the idea that reality is not “out 
there” waiting to be discovered, but is actively produced 
– “constructed” – by those participating in it. For a full 
account of the varieties of constructivism, see Holstein 
and Gubrium [13].
Integration: an empirical example
Our case study is the Microbicides Development 
Programme’s MDP 301 phase III trial of the candidate 
microbicide PRO 2000. MDP 301 was a randomized, 
double-blind, placebo-controlled trial to test the safety 
and eﬃ   cacy of PRO 2000 for the prevention of vaginally 
acquired HIV infection. Th   e trial recruited 9385 women 
at six sites in Uganda, Tanzania, Zambia and South 
Africa and randomized them to receive either placebo or 
PRO 2000 gel. Women were asked to insert an applicator 
of gel within one hour before every act of sexual inter-
course. Th  ey received regular HIV testing and counsel-
ling, promotion of safer sex practices, free condoms and 
diagnosis and treatment of sexually transmitted 
infections. Details of the trial’s methodology and results 
have been published elsewhere [14,15].
Early in the trial design phase, a decision was made to 
include a substantial social science component that would 
assess and contribute to the accuracy of the clinical data 
on sexual behaviour, gel adherence and condom use [16, 
17]. Th   e social science component also involved assessing 
product acceptability and participants’ comprehension of 
the study, including informed consent procedures.
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case record form (CRF), a closed-response questionnaire 
administered in the clinic. On this, women were asked to 
report their sexual behaviour, such as the number of 
times they had sex in the previous week and the number 
of times they used the gel or a condom. At each site, 
approximately 100 women were additionally randomized 
to take part in social science procedures (7.7% of trial 
participants); this included completing pictorial coital 
diaries at home and taking part in in-depth interviews, 
which elicited reports of the same behaviours over the 
same time period as the CRF and coital diaries. During 
these interviews, women were also asked about any 
discrepancies in their reports of their sexual behaviour 
on the diﬀ  erent instruments [16, 17].
Measuring behavioural outcomes: shifting meaning of key 
terms and behaviours
Th   e mixed-method approach was based on the 
assumption that it would be possible to match data from 
the same women for the same time period collected using 
diﬀ   erent research tools. Any discrepancies would be 
discussed with participants and, hopefully, resolved. 
Early on, it became clear that there were substantial 
discrepancies between data from the diﬀ  erent sources, 
mainly relating to the reporting of numbers of sex acts. 
At the end of the trial, there were inconsistencies in 60% 
of the data (predominantly CRF data), though most of 
these (80%) were resolved during discussion with 
participants [16]. Th  is process highlighted the fallibility 
and fragility of the CRF data, the main data for the trial.
Analysis of the in-depth interviews revealed reasons for 
much of the inaccuracy: misunderstandings, recording 
errors and forgetfulness. However, other factors emerged. 
Various categories that were important to the trial in 
terms of measuring adherence to study product and the 
proportion of exposures to HIV covered by the gel or a 
condom, and which were assumed to be constant and 
universal, turned out to vary between study locations and 
individuals or to be ambiguous and to change for partici-
pants as they were questioned about them. For example, 
structured questions about time periods focused on 
“days”, “weeks” and “months” on the assumption that 
these terms meant the same thing to researchers and 
participants across the diﬀ  erent locations and through 
time. However, in practice, “the last month” could be 
interpreted as the last 30 days, or what remains of this 
calendar month, or the time since the last clinic visit, and 
“the last week” could mean the last seven days, or the 
period since last Monday. Th   e lived reality of “day” always 
exceeded attempts to deﬁ   ne it; units of time in the 
context of sexual practice cannot easily be measured by 
the clock, but are embedded in social interactions, in 
artefacts, in the body, and in the environment [18]. Th  is 
is starkly illustrated by the Swahili day, which starts at 
6am and not when the clock turns midnight.
Perhaps even more central to the outcome of the trial 
was the category of “sex act”. Whereas we all know what 
we mean when we say we have “had sex”, this becomes 
complicated when we attempt to clearly deﬁ  ne what an 
“act of sex” is and what separates one sex act from 
another. Th  e complexity increases when working across 
multiple socio-cultural and linguistic settings, where, for 
example, sex may be referred to as “meeting” your 
partner and people distinguish between “sex acts” and 
“rounds”. Th   e trial issued the following deﬁ  nition of a “sex 
act”: “penetrative vaginal sex that may or may not end 
with ejaculation”. In order to collect standardized and 
comparable data, interviewers across all settings were 
required to provide the same deﬁ   nition and ask the 
question in the same way throughout the trial. Th  e 
assumption was that there is a single, ﬁ  xed reality that 
could be measured in a universal and standardized way.
However, as the trial progressed and participants 
became familiar with this deﬁ  nition, the meaning of the 
questions about sex acts (and days and weeks) changed 
for them. What they reported as “one sex act” at the start 
of their participation was not necessarily the same as 
what they reported after months of iteration about the 
trial’s deﬁ  nition of sex. So divergent behavioural realities 
and temporal framing were brought within the logic of 
the structured trial CRF and its categories. Clearly, from 
a trial perspective, this had implications for the reliability 
and validity of data on the numbers of sex acts, but the 
RCT (and quantitative research more generally) does not 
allow for ﬂ  exibility in the wording of questions to record 
these diﬀ   erent realities and take into account their 
shifting meanings.
Because of the rigidity of RCT design, the “messy” data 
on inconsistencies emerging from the qualitative methods 
could not be used to adjust the main dataset used for 
analysis of the trial result. In other words, knowledge of 
the social circumstances of trial data production were 
excluded, even where the cost was a less “accurate” 
version of trial participants’ reported experiences. 
Collaboration between social and biomedical scientists 
over the measurement of sexual behaviour was therefore 
productive but limited; at the outset, it improved the 
validity of trial instruments, but it did not have any 
signiﬁ   cant impact on the main trial data or its 
interpretation.
At the same time that divergent behavioural realities 
were being reclassiﬁ  ed by participants and standardized 
by trial instruments, the behaviours themselves were also 
changing and adapting to the trial. Quite apart from 
changes requested by the trial as a condition for partici-
pation, there is evidence that, for many participants, the 
frequency of sex increased due to the increased sexual 
Montgomery and Pool Journal of the International AIDS Society 2011, 14(Suppl 2):S4 
http://www.jiasociety.org/content/14/S2/S4
Page 3 of 7enjoyment and novelty resulting from gel, and there was 
experimentation, with some participants talking of 
experiencing a second youth. It is also likely that the 
repeated emphasis on the trial deﬁ  nition of sex will have 
had an impact on the reality of sex.
Sexual cultures are dynamic, they change naturally, and 
they change in response to research. Clinical trial 
research presumes a static ﬁ  eld, dimensions of which can 
be measured but do not change, whereas social theory 
suggests that the mess and ﬂ  uidity of the world can never 
be wholly captured by our attempts to pin it down, as 
well as the productive role of method itself in creating 
alterity:
“Practices generate that which they generate, but 
they also generate Otherness: homogeneity and 
heterogeneity; consistency and inconsistency; 
mensurability and uncountability; that which can 
be pinned down and delineated and that which 
cannot; grids and ﬂ  uids. Residues and resistances 
are not technical failures - though it is possible to 
imagine them in this way. Rather they are intrinsic 
to practice, to being, which is, as it were, always 
more complex than it says or it can know” [19].
Critical, qualitative social science integrated into a 
clinical trial can both minimize the mess and draw atten-
tion to it. By revealing the large numbers of inconsis-
tencies in the dataset upon which the trial result was 
based, social science drew attention to the “hidden work” 
of accomplishing an RCT that usually goes unremarked 
[20, 21]. Such insights can be productive, but also pose a 
challenge, since underscoring the social contingencies of 
the RCT potentially threatens its very existence.
Renewal and production: adjusting the lens
So far, we have discussed how issues of measurement 
were a central tension and site of production at the 
intersection of the social and the biomedical. Qualitative 
social science and epidemiology both oﬀ  er approaches 
and styles of thought that direct one to particular 
questions and analytical foci. Th   is cross-fertilization led 
to interesting and unanticipated research ﬁ  ndings that 
enriched the trial and our knowledge of HIV dynamics. 
As Bryman observes, “Research of all kinds has the 
capacity to oﬀ  er surprising or unexpected ﬁ  ndings, but 
when quantitative and qualitative research are combined 
the possibilities of unplanned or unanticipated outcomes 
are magniﬁ  ed considerably” [7].
Under inﬂ  uence of the trialists’ need for representative 
and quantiﬁ  able data, the social science team increased 
sample sizes well beyond those normal for qualitative 
studies and used random selection, thus making the 
qualitative ﬁ   ndings generalizable to the whole trial 
population. Also, the use of comparison groups made it 
possible to notice, and encouraged the explanation of, 
marginalized or stigmatized behaviours that were 
relevant for the trial but might not have arisen in a small 
convenience sample. For example, anal sex and multiple 
concurrent partners for women arose as new analytical 
domains for the social scientists, based on observations 
from the trial’s large main dataset.
Whereas the trial, by design, took an interest in the 
aggregate, integrated qualitative research could simul-
taneously explore the personal, delving into the nuances 
and complexity of lived social reality. Similarly, the 
tendency to conduct sub-group analyses in large quanti-
tative data sets focuses analytical attention on questions 
that might not otherwise arise. For example, database 
reports showed that at one site, trial participants were 
reporting many more adverse events than participants at 
the other sites. Given that there was no biomedical 
rationale for this, it was assumed to be an artefact of the 
research process, but the question remained as to why it 
existed at this site. Th  e social science team therefore 
decided to look at patterns of symptom reporting and the 
culture of medical research in diﬀ  erent sites, topics that 
may not have arisen without the epidemiological 
rationale of doing so in this context.
If the epidemiology could be said to direct the line of 
sight, the social science suggested the lens through which 
data was collected. As far as possible, this lens was that of 
the people participating in the research rather than that 
of the people who had designed it. Typically in 
biomedical HIV research, questions are posed using pre-
determined categories based on the views of researchers, 
and uniform concepts transposed to a variety of 
geographical and cultural settings. Whereas this framing 
is presumed by biomedical researchers to be objective, or 
aperspectival (“a view from nowhere”, as Goldenberg [4] 
puts it), anthropology refers to this view as the “etic” 
perspective. An “emic” approach, by contrast, enables us 
to take account of local meanings in a given cultural 
context by incorporating the conceptual schemes and 
categories that are meaningful to the study participants 
[22]. Th   is approach proved particularly valuable in terms 
of understanding acceptability, both of trial procedures 
and study product.
For example, whereas microbicide acceptability has 
traditionally been framed in terms of HIV risk and 
individual behaviour change [23], we found that dis-
courses of sexual pleasure and sexual health more broadly 
were at the fore of women and men’s accounts of use [24]. 
Th   e social science foregrounded the disjuncture between 
biomedical conceptions of microbicides and the mean-
ings and uses of gel in the context of users’ everyday lives. 
Although trial participants did not reject biomedical 
knowledge outright, they situated this in terms of their 
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such that the microbicide was conceptualized and 
employed in ways unimagined by drug developers or the 
medical researchers [25].
Similarly, in terms of the acceptability of the trial and 
its procedures, community response was couched in 
terms unlikely to have been captured by closed-response 
questionnaires, involving, at some sites, rumours of 
blood stealing and Satanism [26]. Social science research 
allowed these rumours to be interpreted and addressed 
so that threats to recruitment and retention could be 
minimized. Initial feedback from the social science data 
resulted in tailored community outreach, including, for 
example, invitations to observe clinical waste (including 
blood product) incineration; post-factum interpretations 
can inform future dialogue with communities whose 
members take part in clinical trials.
Communication and compromise across epistemic and 
methodological divides
In MDP, the relationship between social scientists and 
clinical trialists was complex and ambivalent. On the one 
hand, there was a relative degree of equality and mutual 
respect between clinical epidemiologists and social 
scientists, equal representation in trial management and 
coordination bodies, and equity in funding. Th   e very fact 
that a group of clinical trialists agreed to include a large 
qualitative, and potentially critical, social science compo-
nent to such a degree in an important trial was without 
precedent. Trialists contributed substantially to the 
mixed-method design of the social science component, 
engaged in cross-disciplinary debate, and showed a 
striking and unusual degree of reﬂ  exivity and critique 
toward the assumptions underlying the trial method-
ology. Interdisciplinary communication was key to 
sustaining meaningful and productive collaboration, and 
occurred at all levels: within individual clinical sites, 
between clinical and coordinating sites, and among social 
science teams from diﬀ   erent clinical sites. Regular 
interdisciplinary meetings, both face to face and via 
teleconference, brought social and biomedical concerns 
to the table simultaneously.
On the other hand, this collaboration involved com  pro-
mises and adjustments that were largely on the side of the 
social scientists. We pursued an agenda of improving the 
trial, which entailed submitting to the cultural logic of 
the RCT and establishing a multi-level feedback loop to 
communicate with the diﬀ  erent disciplinary teams. By 
“cultural logic” we refer to the requirements of the 
protocol, Good Clinical Practice and Institutional Review 
Boards (IRBs), which sometimes conﬂ   icted with the 
assumptions of social science and qualitative research. 
So, for example, while discussing the ﬂ  uidity of the social 
world and the need for ﬂ  exibility in its measurement, in 
practice we had to agree to limit adjustments to the in-
depth interview guide because this would require new 
IRB approval. In another example, we felt that recording 
a sample of CRF interviews could help improve the data 
collection process, but getting permission from the trial 
to do this was fraught with lengthy debate about protocol 
amendments and new forms of consent for research staﬀ   
conducting the interviews.
Priorities diverged not only at the point of data collection 
but also in expectations about analysis. Where  as we saw 
data collection and interpretation as co  extensive, and 
presumed the need for ﬂ  exibility to adjust the analytical 
lens, the trial required a ﬁ  xed analysis plan upfront. Th  is 
was driven by the desire to reduce bias and weed out the 
researcher’s subjective response or individual discretion in 
relation to the data. Whereas we acknowledged, and 
indeed explicitly incorporated, the researcher, this was 
anathema to clinical trialists, who aimed, and subsequently 
presumed themselves, to be absent from the data. 
Collaboration involved constant attempts by each party to 
assert these principles; social science analysis plans were 
usually only presented in “draft” form.
Finally, the two sides were not monolithic either, or 
rather, there were not so much two sides – clinical trial 
and social science – but a range of views that largely, but 
not exclusively, coincided with the disciplinary 
boundaries. Although most trialists were positivistically 
oriented, some had, or developed, relatively critical and 
reﬂ  exive perspectives, and the views among the social 
scientists ranged from critical anthropological to 
positivistic and applied. In this range of views, the centre 
of gravity was towards the positivistic rather than the 
critical-reﬂ  exive end. As a result, the integration of social 
science in the trial, although productive, could be seen, 
from a critical perspective, to have been more 
administrative than substantial: social science ﬁ  ndings 
were not taken into account in the main trial results and 
the social science had no inﬂ  uence in the standard way in 
which the RCT was conducted.
On the other hand, many of the insights from the social 
science only emerged during the trial, and were accepted 
partly as a result of persistent lobbying during internal 
meetings, and so could not have been taken into account 
in the design of the trial. It is worth noting that the 
proposal for a second MDP trial has replaced the 
standard CRF for behavioural and adherence data with a 
revised version of the main qualitative in-depth interview 
tool from this trial.
Discussion
In this paper, we have described the pragmatic approach 
to combining the social and the biomedical in MDP 
microbicides research. In summary, social science was 
used in four key ways:
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diﬀ   erent methods to validate key behavioural 
measurements.
2 Complementarity: we used qualitative methods to 
elaborate, illustrate and clarify results from the quanti-
tative methods, and quantitative data to critically re-
evaluate the qualitative data, thus aiding interpretation 
of the trial.
3 Development: we used results from the quantitative 
methods to inform qualitative enquiry and vice versa, 
including the design of tools, sampling of research 
subjects and substantive areas of enquiry.
4 Critique: we used social science data and extended 
observation of the functioning of the trial to 
constructively critique the standard RCT approach.
Clinical trials embody a search for coherence based 
upon a notion of stable human subjects, stable bio-
technologies and predictable clinical outcomes. Th  e 
reality is less clean cut: human subjects are not static in 
their behaviours, biotechnologies are not fully pre  deter-
mined, and clinical outcomes may be predictable but are 
also the product of multiple shifting contingencies. It is 
these entanglements that social science integrated in 
clinical trials should be aptly placed to respond to. Yet in 
spite of equity in funding, management structures, 
coordination, and a successful collegiate ethos, collabora-
tion in this case did not result in any extrapolation of 
social science ﬁ  ndings to the main trial result; in spite of 
the inaccuracies uncovered, the CRF remained the source 
of “objective” data in the ﬁ  nal analysis.
RCTs have been recognized as the appropriate research 
design for determining drug safety and eﬃ   cacy even by 
the most critical social scientists. However, social 
scientists have been vocal in their objection to the use of 
the RCT in evaluating non-drug interventions, such as 
health promotion or complex interventions [27].
Vaginal microbicides contain a large dose of both the 
social and the biomedical, and it is therefore ﬁ  tting that 
they be evaluated using RCTs with integrated social 
science. Large phase III microbicide trials are really 
studies of eﬀ   ectiveness rather than eﬃ   cacy;  in  other 
words, they measure the eﬀ  ect of the drug in a real-world 
setting rather than in the controlled conditions of the 
laboratory or clinical research suite. In these (quasi) real-
world settings, the drug does not get used in a vacuum, 
where eﬃ   cacy can be measured based on the assumption 
of use and exposure. Simple causality cannot be inferred. 
Instead, the drug is used in a complex social world of 
inequitable power relations between women and men, 
sexual practices which may aﬀ  ect drug eﬃ   cacy (such as 
vaginal douching and insertion) and social norms of 
commodity sharing and rationing (potentially disrupting 
drug allocation and reducing adherence if a woman’s gel 
supply runs low).
Integrating social science methods is indicative of 
recognition that the experimental method alone is insuf-
ﬁ  cient to measure cause and eﬀ  ect in the social world. It 
responds directly to charges that the RCT is reductionist 
and objectivist; the job now is to advance understanding 
of how social theory and qualitative data can more 
fundamentally inform the results of RCTs.
We argue that RCTs with well-funded integrated social 
science may provide more meaningful results (particu-
larly where the result is ﬂ  at or “negative”) since social 
science can illuminate the interplay of continuous, un-
con  trolled and otherwise unmeasured variables poten-
tially determining biological and behavioural endpoints. 
Th   e solution to the tensions that remain between social 
and biomedical researchers is not for social scientists to 
self-censor, believing that collaboration with epidemio-
logists signals the end of critical and theoretical work, or 
to abandon applied collaboration all together. In our 
experience with MDP, we found colleagues receptive to 
critique, where this was seen as a means of improving the 
trial. In short, the key was to engage, to put social science 
to the task of questioning what good evidence is, and 
how we know it when we see it.
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